- 83 Downloads
Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting α-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks.
Clinical trials have demonstrated that acarbose generally improves glycaemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) managed with diet alone, or with other antidiabetic therapy, as evidenced by decreased postprandial plasma glucose and glycosylated haemoglobin levels. It does not appear to directly alter insulin resistance, but may lower postprandial plasma insulin levels. Fasting plasma glucose, triglyceride and/or cholesterol levels may also be decreased. Acarbose also improved metabolic control in patients with insulin-dependent diabetes mellitus (IDDM), frequently decreasing insulin requirements, although further studies are required in this indication.
Improved metabolic control appears to delay or prevent long term vascular complications of diabetes, and indeed, acarbose appeared to inhibit development of such complications in preliminary animal studies, but this finding requires confirmation in clinical studies.
While acarbose seldom causes systemic adverse effects, it is associated with a high incidence of gastrointestinal disturbances such as flatulence, abdominal distension, borborygmus and diarrhoea, caused by fermentation of unabsorbed carbohydrates. However, these symptoms tend to subside with continued treatment and adherence to an appropriate diet.
Thus, acarbose appears to be a worthwhile adjunctive therapeutic option for patients with NIDDM inadequately managed by diet alone, or with pharmacological therapy, and possibly also for patients with IDDM. However, further long term efficacy and tolerability data are required, particularly in the latter indication.
Acarbose is an oligosaccharide which reversibly inhibits intestinal α-glucosidase enzymes responsible for digestion of complex carbohydrates and disaccharides to absorbable monosaccharides. Thus, acarbose delays postprandial absorption of glucose, resulting in attenuation of postprandial plasma glucose, insulin and triglyceride peaks in healthy volunteers. The beneficial effects of acarbose on postprandial glucose levels have been confirmed in patients with insulin-dependent or non-insulin-dependent diabetes mellitus (IDDM or NIDDM), whereas postprandial insulin and triglyceride levels were only occasionally lowered. Pooled data from several clinical trials indicate that acarbose lowers postprandial and fasting blood glucose levels in patients with NIDDM by approximately 20 and 10%, respectively, the latter presumably by an indirect mechanism. Acarbose does not appear to exert any direct effect on insulin resistance in humans.
By decreasing the hyperglycaemic stimulus to insulin secretion, acarbose attenuates the blood glucose nadir and associated clinical symptoms which occur after carbohydrate ingestion in patients with reactive hypoglycaemia.
Delayed carbohydrate digestion increases the amount of fermentable carbohydrate in the bowel, which does not appear to cause calorie loss, because of metabolism to other absorbable nutrients by colonic microflora, but can induce gastrointestinal adverse effects such as flatulence and borborygmi. Acarbose decreases the postprandial gastric inhibitory polypeptide response, while increasing the enteroglucagon response, and also decreases intestinal absorption of iron. It does not generally appear to lower bodyweight in humans, although this effect has consistently been demonstrated in animal models.
Acarbose decreases serum triglycerides, cholesterol and free fatty acid levels in animal models of diabetes and/or hyperlipidaemia, but in human studies in diabetic and nondiabetic individuals, does not consistently lower fasting plasma triglycerides and produces only occasional decreases in fasting plasma cholesterol.
The Diabetes Control and Complications Trial (DCCT) has demonstrated that optimal control of blood glucose levels can retard long term complications of diabetes. Indeed, acarbose decreases levels of glycosylated haemoglobin in patients with diabetes, and glycosylation of other body proteins in preliminary animal studies. Moreover, acarbose appeared to inhibit development of renal, cardiovascular, retinal, and neurological complications in various animal models of diabetes and/or hyperlipidaemia. The latter findings await confirmation in clinical studies.
Consistent with its intestinal site of action, acarbose is minimally (<2%) absorbed in unchanged form following oral administration to healthy volunteers. However, it is rapidly and extensively metabolised by intestinal digestive enzymes, and absorption of metabolites formed in the gut yields a biphasic pattern of absorption in studies with radiolabelled acarbose, with separate peaks at 1 to 2 and 6 to 24 hours. Administration of acarbose 300mg 3 times daily for 90 days to healthy volunteers did not result in accumulation.
Acarbose has a small volume of distribution (0.32 L/kg) and was minimally bound to animal plasma proteins at concentrations ≥ 1 μg/L, and 98% bound at 0.008 μg/L. Acarbose and/or its metabolites were secreted into breast milk and penetrated across the placental barrier in rats.
Approximately 35% of an orally administered dose of acarbose is excreted in the urine, virtually all in metabolised form, and approximately 50% in the faeces. The total body clearance of acarbose was around 600 L/h and values of up to 39.5 hours have been reported for the terminal elimination half-life.
In noncomparative and placebo-controlled studies of 2 to 12 months’ duration, acarbose generally improved metabolic control in patients with NIDDM, whether used with diet alone, or with other antidiabetic agents, including sulphonylureas, biguanides or insulin. Postprandial plasma glucose levels were lowered by approximately 2 to 3 mmol/L and glycosylated haemoglobin levels were also decreased. Fasting plasma glucose and triglyceride levels, and insulin requirements, were also occasionally decreased. Acarbose was not effective in some patients, possibly reflecting low dosages used and/or severe carbohydrate restrictions in some instances, or lack of sensitivity of intestinal α-amylases to acarbose.
Acarbose tended to be slightly less effective than sulphonylureas and biguanides, particularly with regard to effects on fasting plasma glucose, but was at least as effective as guar gum in 1 study.
Acarbose has been less well studied in patients with IDDM, but improved glycaemic control, as evidenced by improved daily blood glucose profiles and decreased glycosylated haemoglobin levels, and frequently, decreased insulin requirements. It may also lower the risk of late hypoglycaemic episodes (those occurring several hours after a meal) in patients with IDDM.
Data from preliminary studies indicated that acarbose might be useful in patients with reactive hypoglycaemia, dumping syndrome and types IIb or IV hyperlipidaemia, but to date no large-scale studies appear to have been performed in these indications.
Gastrointestinal disturbances such as flatulence, abdominal distension, diarrhoea and borborygmus, caused by fermentation of unabsorbed carbohydrate in the bowel, are the most common adverse effects associated with acarbose therapy and may occur in up to two-thirds of patients. These symptoms generally improve with continued treatment, and may be minimised by initiating therapy at a low dosage and adherence to diet. The tolerability of acarbose in children aged 5 to 16 years is similar to that in adults.
Systemic adverse effects are rare during acarbose therapy. However, analysis of data from phase III US studies indicated that anaemia and elevated transaminase levels were significantly more common in acarbose, than in placebo recipients, occurring in 3.8 and 1.1% of patients, respectively.
Acarbose was reported to decrease both peak concentrations and area under the concentration-time curve of metformin by 35% when the 2 drugs were given concurrently to healthy volunteers.
Dosage and Administration
The recommended starting dose of acarbose for patients with NIDDM is 50mg 3 times daily, taken before meals, which may be increased to 100mg 3 times daily after 6 to 8 weeks if necessary, and subsequently to a maximum of 200mg 3 times daily if required. Dosages used in patients with IDDM in clinical trials were similar to those used in NIDDM. Patients receiving the maximum dose should be monitored closely for elevation of serum transaminase levels, preferably at monthly intervals, for the first 6 months of treatment. Contraindications to acarbose use include inflammatory bowel disease, partial intestinal obstruction or predisposition to intestinal obstruction, chronic intestinal disease associated with marked disorders of absorption or digestion, conditions which might be exacerbated by increased intestinal gas formation (such as hernias), and impaired hepatic function. Additionally, acarbose has not been studied in patients with severe renal impairment.
As acarbose may potentiate the hypoglycaemic effects of insulin and sulphonylureas, dosages of these agents may require adjustment when acarbose is administered concurrently. If hypoglycaemia occurs, patients should take glucose rather than carbohydrate foods. The effects of acarbose may be reduced by concomitant administration of intestinal adsorbents such as charcoal, and digestive enzyme preparations such as amylase or pancreatin, and enhanced by concomitant administration of neomycin or cholestyramine.
Unable to display preview. Download preview PDF.
- Anon. Acarbose prescribing information, UK, 1993Google Scholar
- Austenat E. Recent therapy studies with acarbose in type I diabetics. Endokrinologie und Stoffwechsel 12: 19–24, 1991Google Scholar
- Akazawa Y, Koide M, Oishi M, Azuma T, Tashiro S. Clinical usefulness of acarbose and fiber in the treatment of diabetes mellitus. Therapeutics 36: 848–849, 870-875, 1982Google Scholar
- Aubell R, Boehme K, Berchtold P. One-year acarbose treatment of diabetic out-patients. Multicentre study part II: efficacy. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 363–366, Excerpta Medica, Amsterdam, 1982Google Scholar
- Axen KV, Sclafani A. Acarbose decreases insulin resistance in a rat model of NIDDM. Diabetes 39 (Suppl. 1): 49A, 1990 (abstract)Google Scholar
- Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. The effectiveness of acarbose in the treatment of patients with NIDDM. A multi-centre Canadian trial. Submitted for publication 1993.Google Scholar
- Chisholm DJ. Diabetes Monitoring; use of glycated haemoglobin and glycated protein assays. Australian Prescriber 14: 59–61, 1991Google Scholar
- Coniff RF, Innerfield RJ. A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (Bay g 5421) and SFU in the Rx of NIDDM inadequately controlled by maximal SFU. Abstract. Diabetes 39 (Suppl. 1): 109A, 1990Google Scholar
- Decarr LB, Velazquez N, Vasselli JR. Acarbose reduces nonenzymatic glycation of low density lipoprotein (GLDL) and improves lipoprotein composition in sucrose-fed diabetic rats. Abstract. Diabetes 40 (Suppl. 1): 270, 1991Google Scholar
- Deege J, Chantelau E. Alpha-glukosidase inhibition attenuates postprandial plasma glucose response to Coca-Cola™ during insulin-induced hypoglycaemia. In German. Aktuelle Endokrinologie und Stoffwechsel 11: 198–202, 1990Google Scholar
- de Leiva A, Piñón P, Tébar J, Escobar-Jimánez F, de Leiva A, de la Calle H, et al. Efficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos no dependientes de la insulina (tipo II). Med Clin (Barcelona) 100: 368–371, 1993Google Scholar
- Drost H, Hillebrand I, Koschinsky T, Voegtle-Boehringer M, Gries FA. Double-blind cross-over studies on the influence of the glucosidase inhibitor acarbose in type II diabetics. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 330-334, Excerpta Medica, Amsterdam, 1982Google Scholar
- Ebert R, Zarth J, Jakob J, Creutzfeldt W. Gastric effects of acarbose in type 2 diabetics. European Journal of Clinical Investigation 23 (Suppl. 1): A43, 1993Google Scholar
- Escobar-Jiménez F, de Leiva A, Piñón P, Soler J, Tebar J, et al. Efficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos dependientes de la insulina (tipo 1). Medicina Clinica (Barcelona) 100: 488–491, 1993Google Scholar
- Fölsch UR, Lembcke B, Ebert R, Caspary WF, Creutzfeldt W. Sucrose tolerance during treatment with acarbose and/or metronidazole. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 97–106, Exerpta Medica, Amsterdam, 1982Google Scholar
- Gérard J, Luyckx AS, Lefebvre PJ. Acarbose in reactive hypoglycaemia: a double-blind study. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 25–31, 1984aGoogle Scholar
- Goto Y, Toyoda T, Oikawa S, Moruhama Y, Tamura M, et al. Long-term administration of BAY g 5421 (acarbose) in NIDDM [Translated into English from Japanese.] Yakuri to Chiryo 17: 387–401, 1989aGoogle Scholar
- Goto Y, Nakagawa S, Goto Y, Ikeda Y, Hosoya N, et al. Utility of BAY g 5421 (acarbose) on NIDDM, multicentre open study [Translated into English from Japanese.] Kiso to Rinsho 23: 219–239, 1989bGoogle Scholar
- Goto Y, Nakagawa S, Goto Y, Hosoya Y, Orishige H et al. Clinical utility of BAY g 5421 (acarbose) on NIDDM. Multicentre double-blind comparative study [Translated into English from Japanese.] Igaku no Ayumi 149: 591–618, 1989cGoogle Scholar
- Hamada H, Iida R, Mitsuzono T. Effects of acarbose in combination with tolbutamide or insulin on normal and diabetic rats. In Japanese. Yakuri to Chiryo 17: 29–44, 1989aGoogle Scholar
- Hamada H, Iida R, Ishimura K. Effect of acarbose on diabetes in KK mice. In Japanese. Yakuri to Chiryo 17: 17–25, 1989bGoogle Scholar
- Hasche H, Ulm K, Mehnert H. Ambulant additive therapy with acarbose by badly regulated NIDDs. Abstracts of the 12th Congress of the International Diabetes Federation, Madrid, September, 1985, p 227, Elsevier, Amsterdam, 1985Google Scholar
- Hillebrand I, Boehme K. Clinical studies on acarbose during 5 years. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 445–450, Excerpta Medica, Amsterdam, 1982Google Scholar
- Hillebrand I, Englert R. Efficacy and tolerability of a 12-week treatment with acarbose (BAY g 5421), miglitol (BAY m 1099) and glibenclamid. Diabetes 26: 134A, 1987Google Scholar
- Hillebrand I, Graefe KH, Bischoff H, Frank G, Raemsche KD, et al. Serum digoxin and propranolol levels during acarbose treatment. Diabetologia 21:282, 1981Google Scholar
- Hoffmann J. Acarbose and glibenclamid in type-II-diabetes. A comparative study on efficacy and side effects. In German. Münchener Medizinische Wochenschrift 132: 487–490, 1990Google Scholar
- Hollander P, Coniff RF. Two multicenter, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes. Diabetes 40 (Suppl. 1): 307A, 1991Google Scholar
- Innerfield RJ, Coniff RF. A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (Bay g 5421) in the Rx of obese patients with NIDDM Rxed by diet alone. Abstract. Diabetes 39 (Suppl. 1): 211A, 1990Google Scholar
- Jenkins DJA, Taylor RH. Acarbose: dosage and interaction with sugars, starch and fibre. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 86–96, Exerpta Medica, Amsterdam, 1982Google Scholar
- Maruhama Y, Nagasaki A, Kanazawa Y, Hirakawa H, Goto Y, et al. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, faecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohuku Journal of Experimental Medicine 132: 453–462, 1980CrossRefGoogle Scholar
- Mies R, Spengler M. Efficacy of the glucosidase inhibitor acarbose compared to the sulphonylurea glisepoxid on metabolic control of type 2 (non — insulin-dependent) diabetes. Diabetologia 30: 557A, 1987Google Scholar
- Müller FO, Hillebrand I. Acarbose (BAY g 5421) kinetics in healthy volunteers. Acta Pharmacologica et Toxicologica 59 (Suppl. V): 303, 1986Google Scholar
- Petersen K-G. Effects of acarbose in sulphonylurea-treated diabetics in comparison to buformin. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 325–329, Exerpta Medica, Amsterdam, 1982Google Scholar
- Patsch JR, Hopferwieser T, Muhlberger V, Knapp E, Braunsteiner H, et al. Postprandial lipemia in patients with coronary artery disease. Circulation 82 (Suppl. III), abstract no. 1129, 1990Google Scholar
- Pinquier JL, Pello JY, Rey E, de Lauture D, D’Athis P, et al. Effect of acarbose repeated dosing on antipyrine test in healthy volunteers. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 291–294. De Gruyter, Berlin 1992Google Scholar
- Pütter J. Studies on the pharmacokinetics of acarbose in humans. In Brodbeck U (Ed.). Enzyme Inhibitors, pp 139–151, Verlag Chemie, Weinheim, 1980.Google Scholar
- Pütter J, Keup U, Krause HP, Mueller L. Weber H. Pharmacokinetics of acarbose. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp. 38–48, Excerpta Medica, Amsterdam, 1982Google Scholar
- Raptis S, Dimitriadis G, Etzrodt H, Kraraiskos C, Hadjidakis D, et al. The effects of acarbose treatment on release of pancreatic and gastrointestinal hormones in man. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp. 210-215, Excerpta Medica, Amsterdam, 1982Google Scholar
- Sailer D, Roeder G. Treatment of non-insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421). Arzneimittel-Forschung 30: 2181–2185, 1980Google Scholar
- Sakamoto N, Shibata M, Hotta N, Kakuta H, Tomita A, et al. Clinical study on BAY g 5421 (acarbose) for non-insulin-dependent diabetes mellitus (NIDDM). Yakuri to Chiryo 17: 633–649, 1989Google Scholar
- Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefèbvre PJ. Reduction of metformin acute bioavailability by the alpha-glucosidase inhibitor acarbose in normal man. Abstract. European Journal of Clinical Investigation 23 (Suppl. 1): A43, 1993Google Scholar
- Schöffling K, Petzoldt R, Hillebrand I, Schwedes U. Comparison of metformin and acarbose treatment in non-insulin dependent diabetics (NIDDM): a double-blind cross over study. In Melish J.S., et al. (Eds) Genetic environmental interaction in diabetes mellitus. Proceedings of the Third Symposium on Diabetes Mellitus in Asia and Oceania, Honolulu, February 1981, pp 339-343, Excerpta Medica, Amsterdam, 1982Google Scholar
- Shimoyama T, Hori S, Tamura K, Tanida N, Hosomi M, et al. Effects of acarbose on faecal microflora of hyperlipidaemic patients. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 123-136, Excerpta Medica, Amsterdam, 1982Google Scholar
- Spengler M, Cagatay M. Evaluation of efficacy and tolerability of acarbose by postmarketing surveillance. Diabetes und Stoffwechsel 1: 218–222, 1992aGoogle Scholar
- Spengler M, Cagatay M. Assessment of efficacy and tolerability of acarbose in diabetic patients 5–16 years of age. In Lefebvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 290–294. De Gruyter, Berlin 1992bGoogle Scholar
- Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Hormone and Metabolic Research 26 (Suppl.):50–51, 1992aGoogle Scholar
- Spengler M, Hobler H, Cagatay M. Long-term tolerability of acarbose. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 286–288. De Gruyter, Berlin 1992bGoogle Scholar
- Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes. Hormone and Metabolic Research 15 (Suppl.): 46–51, 1985Google Scholar
- Tuomilehto J. Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus — a review. In Creutzfeldt W. (Ed.) Proceedings of the Second International Symposium on Acarbose, Berlin, 1987, pp 105-116, Springer-Verlag, 1988Google Scholar
- Van Gaal L, De Leeuw I, Branolte J. Mineral and vitamin absorption during acarbose treatment. In Alberti et al. (Eds) 11th Congress of the International Diabetes Federation, Nairobi, November 1982, p 35, Excerpta Medica, Amsterdam, 1982Google Scholar
- William-Olsson T, Krotkiewski M, Sjöström L. Relapse-reducing effects of acarbose after weight reduction in severely obese subjects. Journal of Obesity and Weight Regulation 4: 20–32, 1985Google Scholar
- Willms B. Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 163-176. De Gruyter, Berlin 1992aGoogle Scholar
- Willms B. Therapie des typ-II-diabetes-α-glukosidasehemmer (acarbose). Aktuelle Endokrinologie und Stoffwechsel 13: 51–56, 1992bGoogle Scholar
- Young JC, Kurowski TG, O’Hare T, Vasselli JR, Ruderman NB. Effect of oral α-glucosidase inhibitor BAY g5421 on glucose uptake in skeletal muscle. Abstract. Diabetes 40 (Suppl. 1): 25A, 1991Google Scholar